Multicenter International Study, Led by Cedars-Sinai and Presented at American Association of Neurological Surgeons Scientific Meeting, Finds Medical Management Yields Similar Results to Surgery
Recordati Rare Diseases anuncia la publicación de los resultados a largo plazo de la extensión del estudio de fase III LINC 3 de Isturisa® (osilodrostat) en pacientes con enfermedad de Cushing en The European Journal of Endocrinology - Iberonews iberonews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iberonews.com Daily Mail and Mail on Sunday newspapers.
ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022. “Oral octreotide capsules, the first oral somatostatin receptor ligands approved for patients with acromegaly previously controlled on injectable somatostatin receptor
Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be presented onsite at the ENDO 2022 annual meeting being held in Atlanta, Georgia from June
Chicago: Xeris Biopharma Holdings, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult.